Loading…
Monday June 15, 2026 1:45pm - 2:00pm EDT
Component Type: Session

As biomedical science grows more sophisticated, the number of drug development pathways is multiplying exponentially — yet most biopharma companies still deploy capital using strategies that fail to account for this complexity. The result: good science lost to bad finance. This session introduces a quantitative framework for biotech portfolio optimization, combining Monte Carlo simulation with a first-of-its-kind binary optimizer to model correlations, budget constraints, and risk across drug pipelines. Attendees will walk away with a concrete approach to constructing optimal portfolios — allocating capital more strategically, reducing correlated risk, and giving promising therapies a better chance of reaching patients.

Learning Objectives

Understand why advances in biomedical science are paradoxically making capital allocation more difficult — and why traditional financial frameworks are failing to keep pace; Apply Monte Carlo simulation and correlation structure to quantify and diversify drug development risk; Construct optimal portfolios using a binary optimization framework that balances expected return against risk.

Chair

Shomesh Chaudhuri, PHD, MS

Speakers
SC

Shomesh Chaudhuri

Co-Founder, QLS Technologies LLC, United States
Dr. Shomesh E. Chaudhuri is a Co-Founder of QLS Technologies. He's developed portfolio intelligence platforms for several biopharma companies, consulting directly with CEOs, CFOs, and their staffs to help align their financing structures with their scientific and medical objectives... Read More →
Monday June 15, 2026 1:45pm - 2:00pm EDT
Spark Stage The Pennsylvania Convention Center 1101 Arch Street Philadelphia, PA 19107 USA

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Share Modal

Share this link via

Or copy link